M
etformin (1,1-dimethylbiguanide hydrochloride) is a hypoglycemic agent used extensively for the treatment of type 2 diabetes (1-2). Metformin is a biguanide agent, as are buformin and phenformin. The principal function of metformin is to reduce hepatic glucose production and to improve peripheral insulin sensitivity, thus ameliorating hyperglycemia (3) (4) . Metformin has also been shown to enhance glucose uptake in the muscles (5) , while reducing levels of plasma triglycerides (6) and nonesterified fatty acids (7) . Metformin has been shown to activate AMPactivated protein kinase (AMPK) via an LKB1-dependent mechanism (1) (2) 8) .
AMPK is a well-known serine/threonine kinase that functions as an intracellular energy sensor and has been implicated in the modulation of glucose and fatty acid metabolism (8 -9) . AMPK is activated by physiological stimuli including exercise, muscle contraction, and hormones such as adiponectin and leptin, as well as by physiological stresses, glucose deprivation, hypoxia, oxidative stress, and osmotic shock conditions (10 -11) . Once activated, AMPK inhibits gluconeogenesis and lipogenesis while promoting both fatty acid oxidation and lipolysis. Activation of AMPK by the AMPK activators 5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside (AICAR) and metformin has been shown to inhibit the expression of two key hepatic gluconeogenic genes, PEPCK and G6Pase, which, in turn, suppresses gluconeogenesis (12) (13) . However, the molecular mechanism underlying the AMPKmediated transcriptional regulation of PEPCK and G6Pase has not been fully elucidated.
The small heterodimer partner (SHP; NR0B2) is an atypical orphan nuclear receptor that lacks a conventional DNA-binding domain and consists only of a putative ligand-binding domain (14) . SHP represses the transcriptional activity of a number of nuclear receptors (15) (16) (17) (18) (19) (20) (21) (22) , as well as hepatocyte nuclear factor (HNF)-4␣ (NR2A1), FoxO1 (also known as FKHR) (23) , and the forkhead transcription factor FoxA2 (also referred to as HNF-3␤) (24) , which are the primary transcription factors that regulate PEPCK and/or G6Pase expression. Recent evidence suggests that SHP may perform a function in glucose homeostasis by the regulation of hepatic gluconeogenesis. Yamagata et al. (23) showed that the expressions of hepatic gluconeogenic genes, including PEPCK, G6Pase, and fructose 1,6-bis phosphatase (FBP1), are inhibited by bile acids in a SHP-dependent manner. In our previous study, it was shown that SHP inhibits PEPCK, G6Pase, and CYP7A1 expression via the repression of FoxA2-mediated transcriptional activity (24) . However, no study has examined whether SHP expression is induced by pharmacological agents, such as the AMPK activators that suppress hepatic gluconeogenic genes, or whether metformin-induced suppression of hepatic gluconeogenic gene expression is mediated by SHP.
In this study, we investigated whether metformin induces hepatic SHP gene expression and whether this effect is mediated by AMPK. In addition, we have attempted to ascertain whether metformin-induced inhibition of hepatic gluconeogenesis is consequently mediated by SHP. and the livers of the animals were exposed surgically. The liver was first perfused with resuspension buffer (150 mmol/l NaCl, 10 mmol/l KCl, 1 mmol/l NaH 2 PO 4 ⅐2H 2 O, 0.8 mmol/l NaH 2 PO 4 ⅐12H 2 O, 1 mmol/l EGTA, 0.8 mmol/l NaHCO 3 , 10 mmol/l D-glucose, and 10 mmol/l HEPES, pH 7.2) at 30 -50 ml/min for 5-10 min and then perfused with collagenase solution (9.5 g/l Hank's balanced salt solution, 0.8 mmol/l NaHCO 3 , 0.9 mmol/l CaCl 2 ⅐2H 2 O, 10 mmol/l HEPES, and 0.5 g/l collagenase IA [Sigma] , and 50 mg/l trypsin inhibitor, pH 7.5) at 30 -50 ml/min for 5-10 min. After perfusion, the liver was chopped finely in a Petri dish and then filtered through an 85-m pore mesh. The hepatocytes were collected by centrifugation at 800 rpm for 2-5 min at 4°C. The viability of the hepatocytes was measured by trypan blue exclusion and was consistently in excess of 85%. All hepatocytes were seeded onto collagen type 1-coated 60-mm dishes (1 ϫ 10 6 cells/ml; IWAKI Scitech Div, Tokyo, Japan) in William E medium (Sigma). After 6 h of incubation, the medium was exchanged with DMEM without serum, and the hepatocytes were utilized for Northern blot analysis. Northern blot analysis. HepG2, H4IIE, and AML12 cell lines, as well as rat primary hepatocytes were maintained in the indicated media. At a confluence level of ϳ80%, the cells were subjected to serum starvation (medium with 0.5% FBS). After 24 h of starvation, the cells were treated with metformin (0.5-2 mmol/l), 8-br-cAMP (500 mol/l), and dexamethasone (1 mol/l) (cAMP/Dex) and were subsequently infected with adenoviral vectors expressing SHP, AMPK, or siRNA SHP for 24 h in both a time-and dose-dependent manner in both the hepatoma cells and primary hepatocytes. The cells were subsequently harvested at the indicated times, and total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Aliquots of 30 g of total RNA from each of the samples were used for Northern blot analysis as described previously (29) . The probe labeling of each of the cDNAs for SHP, PEPCK, G6Pase, and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) with [␣-32 P]dCTP was performed using a random-primer DNA labeling system (Amersham Biosciences, Little Chalfont, U.K.). The expression of all transcripts was normalized to GAPDH levels. Western blot analysis. H4IIE cells were treated with metformin, AICAR, and compound C for 12 h, and the cells were then harvested and homogenized in lysis buffer containing 50 mmol/l Tris-HCl (pH 8.0), 150 mmol/l NaCl, 5 mmol/l EDTA, 0.5% Nonidet P-40, 100 mmol/l phenylmethylsufonyl fluoride, 1 mol/l dithiothreitol, 1 mg/ml leupeptin, and 1 mg/ml aprotinin. The cell lysates (40 g/lane) were separated via SDS-PAGE on 8% gel, and the proteins were transferred to Hybond-C Extra nylon membranes. The membranes were probed with a monoclonal phospho-AMPK-␣ antibody (Thr 172 [phosphorylated at threonine 172]; Cell Signaling Technology), a polyclonal AMPK-␣ antibody (Cell Signaling Technology), and a polyclonal phospho-acetyl-CoA carboxylase (ACC) (Ser 79 [phosphorylated at serine 79]; Upstate, Charlottesville, VA), and then developed using an ECL Western blot detection kit (Amersham Bioscience). Each of the membranes was also probed with a ␤-actin antibody to verify equal protein loading in each lane. Animals. Seven-week-old male Sprague-Dawley rats (Daehan Biolink, Chungbuk, Korea), each of which weighed 200 -230 g, and 8-week-old female B6-Lep ob/ob mice (Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea) were housed in an animal facility under the following conditions: 22 Ϯ 2°C, 55 Ϯ 5% humidity, and a 12-h light/dark cycle with ad libitum access to water and a standard laboratory diet. Metformin was orally administered (from 50 to 400 mg/kg body wt) to 8-week-old female B6-Lep ob/ob mice in both a time-and dose-dependent manner following an overnight fasting condition (12 h) and feeding condition. The mice were infected with adenoviral vector expressing SHP (1ϫ 10 9 p.f.u.) by tail-vein injection for indicated time points in feeding condition. Livers from metformin-treated and adenovirus-infected mice were used in the preparation of total RNA and Northern blot analysis. Before the isolation of the liver, the blood glucose levels of each mouse were measured at the indicated times with a glucose meter (Accu-Check Active; Roche Diagnostics). All experimental procedures involving animals were approved by the Chonnam National University Institutional Animal Use and Care Committee and conducted in accordance with the National Institutes of Health animal research standards. Statistical analysis. Data are expressed as means Ϯ SEM. ANOVA was used to determine significant differences as detected by Duncan's multiple comparison test. Values of P Ͻ 0.01 were considered to be statistically significant. All experiments were performed at least three times. significantly by metformin in a time-and dose-dependent manner in HepG2, H4IIE, and AML-12 cells (Fig. 1A-C) . In rat primary hepatocytes, SHP gene expression was also increased by metformin treatment, in a pattern similar to that observed in the tested hepatoma cells (Fig. 1D ). SHP gene expression had increased by 6 h and reached maximum levels by 24 h of metformin treatment in majority of the cell lines.
RESULTS

Metformin induces SHP
To test whether metformin regulates SHP promoter activity, we conducted transient transfection assays using a reporter gene containing Ϫ2.2 kb of the human or mouse SHP gene promoter. In HepG2 and AML-12 cells, metformin significantly increased SHP promoter activity in a dose-dependent manner ( Fig. 1E and F) . These results show that metformin regulates SHP gene expression via an increase in SHP promoter activity. AMPK induces SHP gene expression. To investigate whether the regulation of SHP by metformin is mediated by AMPK, we evaluated the effect of AMPK on mRNA levels and SHP promoter activity in primary hepatocytes using an adenoviral vector that expressed either the constitutively active form of AMPK (Ad-AMPK) or the adenovirus dominant negative form of AMPK (Ad-DN-AMPK). Overexpression of AMPK with Ad-AMPK induced SHP gene expression in primary heptatocytes. In contrast, metformin-stimulated SHP gene expression was inhibited by Ad-DN-AMPK ( Fig. 2A) . Ad-AMPK also increased SHP gene expression in both HepG2 and AML-12 cells, whereas metformin-induced SHP gene expression was dramatically repressed by Ad-DN-AMPK in these hepatoma cells (data not shown). In HepG2 and AML-12 cells, both AICAR and the constitutively active AMPK (CA-AMPK) increased SHP promoter activity in a dose-dependent manner, whereas compound C and DN-AMPK inhibited metformin-induced SHP promoter activity ( Fig. 2B and C) . Collectively, these results show that both metformin-induced gene expression and promoter activity of SHP are mediated by AMPK.
We also assessed the levels of AMPK phosphorylation in the presence and absence of metformin, AICAR, and compound C using an anti-phospho-ACC Thr172 AMPK antibody. AICAR and metformin increased ACC and AMPK phosphorylation, whereas compound C caused a reduction in ACC and AMPK phosphorylation, even in the presence of metformin in H4IIE cells (supplemental concentrations for 12 h, and gene expression was evaluated. The expression of two key hepatic gluconeogenic genes, PEPCK and G6Pase, increased in response to cAMP/Dex and was reduced in response to insulin. As shown in Fig. 3A , metformin (0.5 to 2 mmol/l) induced SHP gene expression and repressed the cAMP/Dex-induced expression of PEPCK and G6Pase in a dose-dependent manner in H4IIE cells. The induction of SHP by metformin also inhibited hepatic gluconeogenic gene expression in a time-and dose-dependent manner in AML12 cells (Fig. 3B ) and rat primary hepatocytes (Fig. 3C) . These results indicate that metformin-induced SHP gene expression is associated with the repression of SHP target genes involved in gluconeogenesis in hepatocytes.
SHP mediates metformin-induced inhibition of the promoter activities and expression of hepatic gluconeogenic genes. SHP interacts with and represses a nuclear receptor, LRH-1. However, SHP does not inhibit the LRH-1-related nuclear receptor SF-1 (17, 28, 30) . Because SHP operates as a transcriptional repressor, we examined whether metformin specifically regulates LRH-1 transcriptional activity. Figure 4A shows that metformin inhibited the transcriptional activity of LRH-1 but failed to inhibit the transactivation of SF-1. Moreover, knockdown of SHP via siRNA SHP rescued the repressed transcriptional activity of LRH-1, whereas no change in SF-1 transcriptional activity was observed. These results indi- cate that metformin specifically regulates the nuclear receptors that are specific targets of SHP.
The promoter activity of PEPCK and G6Pase is regulated by the transcription factors HNF-4␣ and/or FoxA2. To determine whether metformin-induced SHP expression regulates the transcription factors involved in the regulation of the PEPCK and G6Pase promoters, we examined the effects of metformin on transactivation by HNF-4␣ and/or FoxA2. In the presence of HNF-4␣, metformin repressed PEPCK promoter activity with a pattern similar to that observed with SHP, and promoter activity was recovered significantly by knockdown of SHP gene expression with siRNA SHP (Fig. 4B) . Similarly, FoxA2-induced G6Pase promoter activity was repressed significantly by SHP and metformin, and this activity was recovered when the cells were treated with siRNA SHP (Fig. 4C) . We also determined that in the presence of FoxO1, metformin inhibited hepatic gluconeogenic gene promoter activity with an effect similar to that observed with SHP, and the activity was recovered as the result of knockdown of SHP gene expression via siRNA SHP (supplemental Fig. 2) . Collectively, these results indicate that metformin-induced SHP gene expression inhibits the function of transcriptional factors that regulate hepatic gluconeogenesis.
To confirm whether metformin-induced downregulation of hepatic gluconeogenic genes is dependent on SHP gene expression, we assessed the effects of SHP on metformininduced inhibition of PEPCK and G6Pase gene expression in H4IIE cells. Overexpression of SHP using adenovirus SHP (Ad-SHP) significantly repressed both cAMP/Dexinduced PEPCK and G6Pase gene expression in a timeand dose-dependant manner (supplemental Fig. 3) . However, SHP knockdown with adenovirus siRNA-SHP reversed metformin-induced inhibition of cAMP/Dex-induced PEPCK and G6Pase gene expression, whereas a control siRNA (Ad-scramble) exerted no discernable effects on the metformin-induced inhibition of hepatic gluconeogenic gene expression (Fig. 4D) . These results indicate that the induction of SHP gene expression by metformin has a significant effect on the downregulation of hepatic gluconeogenesis. Metformin and SHP decrease blood glucose levels and the expression of PEPCK and G6Pase gene in the livers of B6-Lep ob/ob mice. To determine whether metformin-induced SHP inhibits blood glucose levels and hepatic gluconeogenic genes expression in vivo, the expression of SHP and hepatic glucose production were analyzed in the metformin-treated B6-Lep ob/ob mice. As shown in Fig. 5A , blood glucose levels in the fasting condition were significantly decreased by metformin in a dose-dependent manner compared with those in the feeding condition, which are comparable to normal blood glucose levels. However, metformin increased SHP mRNA levels and phosphorylation of ACC and AMPK in a dosedependent manner for 6 h (supplemental Fig. 4) , whereas the expression of gluconeogenic genes was significantly repressed compared with the feeding condition. Interestingly, metformin increased SHP gene expression within 6 h, which repressed PEPCK and G6Pase gene expression resulting in reduction of blood glucose levels (Fig. 5B) . These data suggest that induction of SHP gene by metformin results in decrease of blood glucose levels through the repression of hepatic gluconeogenic gene expression.
To confirm the effects of SHP on blood glucose levels through the repression of hepatic gluconeogenic genes expression, we infected Ad-SHP into B6-Lep ob/ob mice via tail vein injection. To verify the transduction efficiencies of adenovirus-expressing green fluorescent protein-tagged SHP, we examined the mouse livers using fluorescence microscopy at the indicated time period (data not shown). As shown in Fig. 5C metformin regulates hepatic glucose production via the inhibition of hepatic gluconeogenic gene expression in vivo.
DISCUSSION
In this study, we found that metformin increased SHP gene expression via AMPK activation and inhibited the expression of the hepatic gluconeogenic genes PEPCK and G6Pase via upregulation of SHP. The inhibitory effects of metformin on hepatic gluconeogenic gene expression were blocked via the knockdown of SHP using siRNA SHP. Moreover, these effects of metformin, which were characterized in both hepatoma and hepatic cells, were observed to occur in a similar fashion in metformintreated B6-Lep ob/ob mice. SHP gene expression was increased by metformin, and adenovirus-mediated SHP overexpression caused a reduction in the expression of hepatic gluconeogenic genes. Consequently, blood glucose levels were also reduced in the obese mice.
SHP plays a pivotal role in cholesterol and glucose metabolism (15, 23, (31) (32) (33) . The synthesis of bile acid from cholesterol is regulated by the rate-limiting enzyme cholesterol 7␣-hydroxylase (CYP7A1) (19) . Bile acid is an endogenous ligand of the farnesoid X receptor, which can profoundly activate SHP transcription (34) , and SHP decreased the expression of CYP7A1 via the inhibition of LRH-1 activity (19, 35) . Additionally, bile acid-induced SHP can downregulate PEPCK and G6Pase expression by the repression of the transcriptional activity of HNF-4␣, FoxO1, and FoxA2 (23) (24) . However, the correlation between SHP expression and type 2 diabetes, and/or antidiabetic agent, has not been previously elucidated. In this study, we report that metformin, a drug commonly used in the treatment of type 2 diabetes, represses the expression of PEPCK and G6Pase genes by increasing SHP gene expression, both in vitro and in vivo. As the inhibition of hepatic gluconeogenic gene expression by metformin is mediated via an AMPK pathway, we examined whether AMPK caused an increase in SHP expression. Indeed, our data indicated that Ad-AMPK, as well as AICAR, increased SHP gene expression. Furthermore, this induction was abolished in the presence of Ad-DN-AMPK or compound C. These results indicate that metformin-induced SHP gene expression is mediated via AMPK activation. Collectively, these results show that the AMPK-mediated upregulation of SHP gene expression may be one of the mechanisms inherent to the negative regulation of hepatic gluconeogenic genes by metformin.
As previously mentioned, SHP inhibits PEPCK and G6Pase gene expression via the repression of HNF-4␣, FoxO1, and FoxA2 activity (23) (24) . Thus, we determined whether HNF-stimulated gluconeogenic genes can be downregulated by metformin-induced SHP. In the present study, it was demonstrated that metformin inhibited HNF-4␣-, FoxO1-, and/or FoxA2-stimulated PEPCK and/or G6Pase promoter activity and that this repression was abolished by siRNA SHP. Overall, the results of the present study demonstrate that metformin can inhibit HNF-stimulated PEPCK and G6Pase promoter activity via the induction of SHP. In addition, the expression of hepatic gluconeogenic genes is also modulated by cAMP and glucocorticoid receptor, which are stimulated by glucagon and glucocorticoid, respectively (15, 36) . Our data indicated that SHP inhibited cAMP/Dex-induced PEPCK and G6Pase gene expression. However, when endogenous SHP was blocked, metformin failed to downregulate the cAMP/ Dex-stimulated expression of PEPCK and G6Pase. AMPK activation causes a rapid reduction in PEPCK and G6Pase expression via the inhibition of the transcriptional activity of HNF-4␣ and the stabilization of FoxO1 (37) (38) . Our data also indicated that PEPCK and G6Pase expression were reduced in the presence of metformin within a short period of time. Therefore, we propose that metformin may regulate the expression of hepatic gluconeogenic genes via two different pathways. The first of these is a short-term pathway, involving the protein stabilization or phosphorylation of AMPK-targeted transcription factors and coactivators, and the second is a long-term effect exerted via the induction of SHP gene expression due to metformin treatment. Metformin was recently shown to reduce significantly blood glucose levels and hepatic gluconeogenic gene expression in the livers of obese and diabetic mice (39) . The results of our study have demonstrated that metformin induces SHP gene expression, which, in turn, reduces the expression of hepatic gluconeogenic genes and blood glucose levels in B6-Lep ob/ob mice. Consistent with our previous observations, we have also determined that the adenovirus-mediated overexpression of SHP inhibited the expression of PEPCK and G6Pases and also reduced blood glucose levels in B6-Lep ob/ob mice. Collectively, our results indicate that metformin-induced inhibition of hepatic gluconeogenesis is mediated via the upregulation of SHP gene expression.
In conclusion, metformin causes increases in hepatic SHP gene expression via an AMPK-dependent pathway and also results in the reduction of hepatic glucose production in vivo. The results of the present study suggest that the regulation of SHP gene expression and promoter activity by metformin may represent a novel pathway that could be modulated to enhance the treatment of type 2 diabetes. To elucidate more clearly the role of SHP in AMPK-mediated hepatic glucose metabolism, it will be useful to generate liver-specific SHP knock-out animals in the future.
